|
 "The safety assessment of glyphosate has not changed since the time
of the acquisition. If that were to change and we were to find that
something was missed during the due diligence we would act
accordingly. But that is not the case," Bayer Chief Executive Werner
Baumann was quoted as saying by German daily Handelsblatt.
He was responding to a question on whether the legal risks from
glyphosate would have to be reviewed.
However, he added that the full extent of the current glyphosate
litigation was not foreseeable when Bayer assessed the value of
Monsanto, according to the interview published on Thursday.
Bayer completed its $63 billion acquisition of Monsanto in June.
[to top of second column] |
Bayer shares have lost more than 10 percent since Monsanto was
ordered this month to pay $289 million in damages in the first of
possibly thousands of U.S. lawsuits over claims it did not warn of
the cancer risks of glyphosate-based weedkillers such as Roundup.
Bayer has vowed to appeal the verdict, saying it was at odds with
scientific evidence and regulators' conclusions.
Bayer was due to hold an analyst call on the glyphosate litigation
at 1200 GMT.
(Reporting by Ludwig Burger; Editing by Douglas Busvine and Susan
Fenton)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
